Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - Canaccord Genuity has reiterated its Buy rating and $12.00 price target on Fractyl Health Inc (NASDAQ:GUTS) following promising clinical trial results presented at the American Diabetes Association conference.
The company shared follow-up data from the open-label cohort of its ongoing Phase 3 trial for its Revita procedure, showing that 12 of 13 patients maintained or lost weight three months after stopping tirzepatide and undergoing the procedure.
The median weight change remained stable from month one to month three, according to Canaccord, which noted the consistency of patient responses despite the small sample size.
This performance compares favorably to typical outcomes when patients discontinue tirzepatide without the Revita procedure, which typically results in average weight regain of approximately 6% at three months.
Canaccord expects more comprehensive data, including results from a control arm to better assess comparative effectiveness, to be available in the third quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.